IL299966A - Bifunctional molecules targeting PD-L1 and TGF- in the cell - Google Patents

Bifunctional molecules targeting PD-L1 and TGF- in the cell

Info

Publication number
IL299966A
IL299966A IL299966A IL29996623A IL299966A IL 299966 A IL299966 A IL 299966A IL 299966 A IL299966 A IL 299966A IL 29996623 A IL29996623 A IL 29996623A IL 299966 A IL299966 A IL 299966A
Authority
IL
Israel
Prior art keywords
tgf
beta
bifunctional molecules
molecules targeting
targeting
Prior art date
Application number
IL299966A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lepu Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Biopharma Co Ltd filed Critical Lepu Biopharma Co Ltd
Publication of IL299966A publication Critical patent/IL299966A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL299966A 2020-07-28 2021-07-27 Bifunctional molecules targeting PD-L1 and TGF- in the cell IL299966A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020105286 2020-07-28
CN2021098476 2021-06-04
PCT/CN2021/108643 WO2022022503A1 (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting pd-l1 and tgf-beta

Publications (1)

Publication Number Publication Date
IL299966A true IL299966A (en) 2023-03-01

Family

ID=80037607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299966A IL299966A (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting PD-L1 and TGF- in the cell

Country Status (9)

Country Link
US (1) US20230287125A1 (https=)
EP (1) EP4188950A4 (https=)
JP (3) JP2023540436A (https=)
KR (1) KR20230050356A (https=)
CN (4) CN121319180A (https=)
AU (1) AU2021317376A1 (https=)
IL (1) IL299966A (https=)
PH (1) PH12023550193A1 (https=)
WO (1) WO2022022503A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508210A (ja) * 2023-02-20 2026-03-10 中山康方生物医▲藥▼有限公司 ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108779180B (zh) * 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
EP3369745B1 (en) * 2016-08-04 2021-09-29 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 nanobody and use thereof
EP3551659A1 (en) * 2016-12-08 2019-10-16 Eli Lilly and Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
AU2018264455B2 (en) * 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019185029A1 (en) * 2018-03-29 2019-10-03 I-Mab Anti-pd-l1 antibodies and uses thereof
BR112021003093A2 (pt) * 2018-08-22 2021-05-11 Merck Patent Gmbh tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
US12559539B2 (en) * 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
US10851157B2 (en) * 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US11028174B1 (en) * 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
CN112940134B (zh) * 2021-05-11 2021-09-03 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白

Also Published As

Publication number Publication date
CN119462927B (zh) 2025-07-29
EP4188950A1 (en) 2023-06-07
PH12023550193A1 (en) 2024-06-24
WO2022022503A1 (en) 2022-02-03
JP2023540436A (ja) 2023-09-25
JP2025010203A (ja) 2025-01-20
KR20230050356A (ko) 2023-04-14
CN116348493B (zh) 2025-10-17
CN119409832B (zh) 2025-08-01
EP4188950A4 (en) 2025-01-22
CN121319180A (zh) 2026-01-13
US20230287125A1 (en) 2023-09-14
JP2026015500A (ja) 2026-01-29
CN116348493A (zh) 2023-06-27
JP7846734B2 (ja) 2026-04-15
CN119462927A (zh) 2025-02-18
CN119409832A (zh) 2025-02-11
AU2021317376A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
IL283958A (en) Bifunctional compounds for lysosomal targeting and related compounds and methods
IL267856A (en) Compositions comprising a bifunctional protein targeting pd-l1 and tgfb
IL287765A (en) TIGIT and FDI-1/TIGIT binding molecules
EP4172216A4 (en) BIFUNCTIONAL SUPERKINE AND USES THEREOF
EP3715377A4 (en) BIFUNCTIONAL FUSION PROTEIN TARGETING CD47 AND PD-L1
ZA201903308B (en) Conjugated biological molecules, pharmaceutical compositions and methods
SG11202001208XA (en) Rna targeting methods and compositions
EP3595719A4 (en) LINKER UNITS AND MOLECULAR CONSTRUCTIONS WITH IT
EP3774919A4 (en) Constructs targeting cd22 and uses thereof
WO2010033771A3 (en) Modulators of hsp70/dnak function and methods of use thereof
EP4408891A4 (en) ANTIBODIES TARGETING BAFF-R AND THEIR USE
EP3917313A4 (en) ANTI-CD45 MOLECULES AND DERIVATIVES THEREOF
IL284781A (en) LILRB3 binding molecules and uses thereof
IL299966A (en) Bifunctional molecules targeting PD-L1 and TGF- in the cell
EP4144763A4 (en) BIFUNCTIONAL PROTEIN AGAINST PD-1 AND TGF-BETA
EP3634489A4 (en) IMPROVED METHODS FOR GENERATING SMALL MOLECULAR DEGRADERS AND DIMERIZERS
EP4294392A4 (en) TARGETED BIFUNCTIONAL DEGRADING AGENTS AND METHODS OF USE THEREOF
HK40130450A (zh) 靶向PD-L1和TGF-β的双功能分子
EP4014189A4 (en) SYSTEMS AND METHODS FOR TARGETING PROMOTIONAL MATERIALS
EP3611557A4 (en) LASER PLATE, LASER ARRANGEMENT DEVICE AND LASER DISPLAY
IL311510A (en) D3 binding molecules and uses thereof
IL285585A (en) fcmr-binding molecules and their uses
HK40063196A (en) Bifunctional molecules for lysosomal targeting and related compositions and methods
EP3914297A4 (en) ANTIBODY-DNA CONJUGATES AND HPV DETECTION AND TREATMENT
HK40105591A (en) Targeted bifunctional degraders and methods using same